Krystal Biotech, Inc. (KRYS) - What Are Researchers Thinking About This Stock?

Key Points

• Analysts remain broadly bullish: Krystal Biotech has a consensus “Buy” rating from 14 analysts, with an average 12-month price target of $377.20. Recent firms including Goldman Sachs, TD Cowen, Citigroup and Bank of America raised or initiated positive coverage.
• Institutional ownership is substantial: Institutional investors and hedge funds own 86.29% of KRYS, with several large investors recently increasing or initiating positions.
• Quarterly results exceeded expectations: Krystal reported adjusted earnings of $1.79 per share versus the $1.70 consensus estimate, while revenue of $119.22 million came in slightly below analysts’ $120.93 million forecast.

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) has received a consensus recommendation of "Buy" from the fourteen analysts that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold recommendation, ten have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $377.20.

KRYS has been the subject of a number of recent analyst reports. Wall Street Zen lowered shares of Krystal Biotech from a "buy" rating to a "hold" rating in a report on Saturday, June 20th. The Goldman Sachs Group started coverage on shares of Krystal Biotech in a report on Thursday, September 24th. They issued a "buy" rating and a $441.00 price objective on the stock. TD Cowen upped their price objective on shares of Krystal Biotech from $306.00 to $403.00 and gave the company a "buy" rating in a research report on Thursday, June 18th. Citigroup upped their price objective on shares of Krystal Biotech from $378.00 to $386.00 and gave the company a "buy" rating in a research report on Tuesday, August 4th. Finally, Bank of America raised their target price on Krystal Biotech from $392.00 to $400.00 and gave the company a "buy" rating in a research note on Monday, September 21st.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $359.32, for a total value of $8,983,000.00. Following the sale, the insider owned 1,302,145 shares in the company, valued at approximately $467,886,741.40. This represents a 1.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino Rossi sold 25,000 shares of the company's stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $329.12, for a total value of $8,228,000.00. Following the sale, the director owned 50,000 shares in the company, valued at $16,456,000. The trade was a 33.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 13.10% of the stock is currently owned by insiders.

Institutional Trading of Krystal Biotech

Large investors have recently modified their holdings of the company. Hsbc Holdings PLC purchased a new stake in shares of Krystal Biotech during the 2nd quarter worth about $3,653,000. Bank of America Corp DE lifted its holdings in shares of Krystal Biotech by 36.6% during the 1st quarter. Bank of America Corp DE now owns 260,647 shares of the company's stock valued at $67,330,000 after buying an additional 69,840 shares during the last quarter. Assetmark Inc. bought a new stake in shares of Krystal Biotech in the 1st quarter valued at approximately $816,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Krystal Biotech in the 2nd quarter valued at approximately $3,865,000. Finally, Corient Private Wealth LP grew its stake in shares of Krystal Biotech by 767.4% in the 2nd quarter. Corient Private Wealth LP now owns 30,558 shares of the company's stock valued at $11,357,000 after buying an additional 27,035 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.

Krystal Biotech Stock Up 0.1%

Shares of KRYS stock opened at $332.07 on Tuesday. Krystal Biotech has a fifty-two week low of $179.19 and a fifty-two week high of $382.54. The firm's 50 day moving average price is $340.43 and its two-hundred day moving average price is $321.57. The stock has a market cap of $9.83 billion, a price-to-earnings ratio of 41.61 and a beta of 0.50.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.70 by $0.09. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. The company had revenue of $119.22 million during the quarter, compared to analyst estimates of $120.93 million. On average, equities analysts forecast that Krystal Biotech will post 7.47 EPS for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company uses engineered herpes simplex virus type 1 (HSV-1) vectors designed to deliver functional genes to targeted tissues, with the goal of treating diseases caused by genetic mutations.

Krystal Biotech's lead product, VYJUVEK (beremagene geperpavec-svdt), is a topical gene therapy approved in the United States for the treatment of wounds in patients with dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and recurrent blistering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.